Neoadjuvant PD1/PD-L1 Blockade Combined with Chemotherapy Associated with High Resectability and Pathological Responses in Borderline Resectable or Unresectable Stage III NSCLC By Ogkologos - June 3, 2025 403 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a multicentre cohort study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR ‘Scandinavian quality and Singaporean efficiency’: what the autumn statement means for... November 17, 2022 Embracing Lung Cancer Survivorship August 3, 2021 EMA Recommends Granting a Marketing Authorisation for Relugolix March 24, 2022 Maintenance Regorafenib Significantly Delays Disease Progression After First-Line Treatment in Patients... April 28, 2025 Load more HOT NEWS Expanding Research on Dormant Cancer Cells Aims to Prevent Metastasis Biomarker Data from the KAITLIN Study in High-Risk Early Breast Cancer FDA Approves BCMA-Targeted CAR T-Cell Therapy for Multiple Myeloma Learning to Live With Cancer: A Survivor’s Story
